Avi J Cohen, Laura R Glick, Seohyuk Lee, Yukiko Kunitomo, Derek A Tsang, Sarah Pitafi, Patricia Valda Toro, Nicholas R Ristic, Ethan Zhang, George B Carey, Rupak Datta, Charles S Dela Cruz, Samir Gautam
{"title":"Nonutility of procalcitonin for diagnosing bacterial pneumonia in patients with severe COVID-19.","authors":"Avi J Cohen, Laura R Glick, Seohyuk Lee, Yukiko Kunitomo, Derek A Tsang, Sarah Pitafi, Patricia Valda Toro, Nicholas R Ristic, Ethan Zhang, George B Carey, Rupak Datta, Charles S Dela Cruz, Samir Gautam","doi":"10.1080/20018525.2023.2174640","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection.</p><p><strong>Methods: </strong>We retrospectively identified 185 patients hospitalized with severe COVID-19 who underwent lower respiratory culture; 85 had evidence of bacterial superinfection. Receiver operating characteristic curve and area under the curve (AUC) analyses were performed to assess the utility of procalcitonin for diagnosing superinfection.</p><p><strong>Results: </strong>This approach demonstrated that procalcitonin measured at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). The AUC not affected by exposure to antibiotics, treatment with immunomodulatory agents, or timing of procalcitonin measurement.</p><p><strong>Conclusion: </strong>Static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":"10 1","pages":"2174640"},"PeriodicalIF":1.8000,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/b5/ZECR_10_2174640.PMC9930745.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Clinical Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20018525.2023.2174640","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Patients hospitalized with COVID-19 are at significant risk for superimposed bacterial pneumonia. However, diagnosing superinfection is challenging due to its clinical resemblance to severe COVID-19. We therefore evaluated whether the immune biomarker, procalcitonin, could facilitate the diagnosis of bacterial superinfection.
Methods: We retrospectively identified 185 patients hospitalized with severe COVID-19 who underwent lower respiratory culture; 85 had evidence of bacterial superinfection. Receiver operating characteristic curve and area under the curve (AUC) analyses were performed to assess the utility of procalcitonin for diagnosing superinfection.
Results: This approach demonstrated that procalcitonin measured at the time of culture was incapable of distinguishing patients with bacterial infection (AUC, 0.52). The AUC not affected by exposure to antibiotics, treatment with immunomodulatory agents, or timing of procalcitonin measurement.
Conclusion: Static measurement of procalcitonin does not aid in the diagnosis of superinfection in severe COVID-19.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
